NCT07927023
A Study to Learn About a Medicine (Called Elranatamab) in People With Relapsed Refractory Multiple Myeloma
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 1 version: 1 with changes below.
- Study First Submitted
Endpoints
Primary
Real World Progression Free Survival (rwPFS)
Timeframe: From the index date through the end of the study period, approximately 6 months.
Overall Survival (OS)
Timeframe: From the index date through the end of the study period, approximately 6 months.
Time to next treatment (TTNT)
Timeframe: From the index date through the end of the study period, approximately 6 months.
Arms and interventions
Elranatamab
Patients treated with elranatamab from the MagnetisMM-5 trial
Standard of care
Patients treated with standard-of-care therapies from real-world data source
Drugs: Elranatamab, Standard of Care